ELSEVIRE Global Medical News
Search Elsevier Global Medical News
Clinical Neurology News
 
 
  Diamond Headache   American Academy of Neurology   American Headache Society
 
This news site is not sanctioned by, nor part of, the Diamond Headache Foundation, The American Academy of Neurology OR The American Headache Society.
News covering selected sessions related to migraine from 2008 medical conferences.
Diamond Headache Clinic Research and Educational Foundation Annual Research Summit Scottsdale, Arizona February 18-22, 2008
 
 
  Gender Based issues in Epilepsy Management
 
  Migraine Preventative therapies
 
  Distinquising Between Migraine and Tension Headache
 
Perimenopuasl Issues and Migraine
 
  Migraine Headache-Diagnosis and Treatment
 
  Biology of Migraine and other Headaches
 
  Exertional Headache: Uncommon, Usually Benign,
but Worrisome
 
  Vertigo, Dizziness Often Reported With Migraine, but Are They Related?
 
  Central Sensitization and Cutaneous Allodynia Implication on Migraine Treatment
 
  Expect the Unexpected When Headache Occurs in Older Patients
 
  Often Implicated, the Eye Rarely Causes Headache
 
Defining the Complicated Migraine
 
Studies Reveal Migraine with Aura is a Risk Factor for Heart Disease
 
Hormonal Therapies for Migraine: Risks vs Benefits
 
Menstrual Migraines
 
Cluster Headache
 
Emergency Department Treatment of Headache
 
 
  Half of Female Migraine Related to Menstrual Cycle  
BY MAURY BREECHER
Contributing Writer
SCOTTSDALE, ARIZ. (ECCC)— As many as 60% of all migraines experienced by women are related to the menstrual cycle, reported Dr. Lisa K. Mannix on February 19 at the annual headache symposium sponsored by the Diamond Headache Clinical Research and Education Foundation.
“For some women their menstrual periods work as a trigger for those headaches,” said Dr. Mannix, the medical director of Headache Associates in Westchester, Ohio. “Those women can benefit from hormonal therapy such as estrogen supplements during the week of their period, or even continuous oral contraceptive therapy through an extended period of time.”
Menstrual migraine (MM) can be either pure menstrual migraine (PMM)—a headache that occurs only during the time of the period—or it can be menstrually-related migraine, a headache that occurs at other times of the month as well as during the period, explained Dr. Mannix. About 10% of women have PMM, 50% have menstrually-related migraines, and migraine unrelated to menses accounts for the remaining percentage of headache, she said.
The clinical characteristics of MM in the general population may not be much different from non-menstrual migraine attacks. However, in clinic populations, doctors see MMs that are more severe, that are less responsive to acute therapy, are more likely to cause work-related disability, and more likely to recur, she said (Obstet Gynecol. 2003;102:835-842; Headache. 2004;44:120-130).
In an interview following her presentation, Dr. Mannix explained that treatments for MM are similar in many ways to treatment of other types of migraines: starting with keeping a diary or a calendar to track the occurrence of those headaches, and then treating them quickly, especially those that are more severe and disabling.
She added that triptans are a first-line choice for the acute treatment of MM and that doctors should encourage their patients to keep headache diaries to track the occurrence of headache.
“Headache diaries and calendars are one of the most useful tools we have for both the diagnosis as well as the management of migraine, particularly with menstrual migraine, as the calendar can track when the headaches occur in relationship to their menstrual cycle,” said Dr. Mannix.
To prevent MM, she recommended the use of conventional prophylactic drugs but said a boosted dosage might be necessary during the perimenstrual period. She also recommended 400 to 600 mg of magnesium daily, and hormonal interventions either monophasic, low dose contraceptives, supplemental estrogen (0.1-mg patch during menses), or continuous combination hormonal contraceptive dosing.
Copyright 2008 Elsevier Custom Conference Coverage. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the copyright owner. No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, the Publisher recommends that independent verification of diagnoses and drug dosages should be made. Opinions expressed in this publication are those of the original authors and do not necessarily reflect those of the Publisher, the sponsor, or the editors. Elsevier assumes no liability for any material published herein.
 

Terms of Use                                    Privacy Policy                                    Contact Us

 
  Copyright ©2010 Elsevier/International Medical News Group
  5635 Fishers Lane, Suite 6000
Rockville, MD 20852
Rights reserved Clinical Neurology News Network